Identification of Prognostic Factors and New Therapeutic Targets in Cutaneous Lymphomas
LYMPHOTEQ
1 other identifier
interventional
500
0 countries
N/A
Brief Summary
Cutaneous lymphomas are a heterogeneous group of extra-nodal lymphomas. The prognosis of cutaneous lymphomas is extremely variable from one subject to another. In the majority of cases, there is no cure for cutaneous lymphomas. Cutaneous lymphomas primarily affect the skin, and secondarily the blood, lymph nodes and possibly other organs. The discovery of new molecular prognostic factors will allow a better identification of patients at high risk of aggressive evolution and the implementation of a personalized therapeutic strategy. The identification of new therapeutic targets is necessary in order to develop new innovative treatments for cutaneous lymphomas.The primary objective is to identify novel molecular prognostic factors associated with 5-year overall survival in cutaneous lymphoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Sep 2020
Longer than P75 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 17, 2020
CompletedFirst Posted
Study publicly available on registry
August 20, 2020
CompletedStudy Start
First participant enrolled
September 30, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2045
ExpectedStudy Completion
Last participant's last visit for all outcomes
September 30, 2050
August 20, 2020
August 1, 2020
25 years
August 17, 2020
August 17, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
overall survival
5 years
Secondary Outcomes (3)
Progression free survival
5 years
Progression free survival
10 years
Overall survival
10 years
Study Arms (1)
Patients with primary cutaneous lymphoma
OTHERInterventions
* An additional punch from lesion skin as part of a skin biopsy performed as part of routine care. * an additional blood sample will be collected for research during a blood test performed as part of the patient's routine care. * In patients with clinical superficial lymphadenopathy or detected by imaging, and undergoing a superficial lymph node biopsy as part of the care, a core biopsy will be dedicated to research.
Eligibility Criteria
You may qualify if:
- Age\> 18 years old
- Informed consent signed by the patient
- Suspicion of primary cutaneous lymphoma or confirmed lymphoma according to WHO/ISCL/EORTC criteria
You may not qualify if:
- Patient under guardianship or curatorship
- Lack of affiliation to social security
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 17, 2020
First Posted
August 20, 2020
Study Start
September 30, 2020
Primary Completion (Estimated)
September 30, 2045
Study Completion (Estimated)
September 30, 2050
Last Updated
August 20, 2020
Record last verified: 2020-08